Three New Vaccines Target Ebola Outbreak in Central Africa

After years of fighting one type of Ebola with existing vaccines, scientists are finally getting the tools and funding they need to combat a different strain threatening Central Africa right now.

The Coalition for Epidemic Preparedness Innovations just announced up to $62 million to develop three vaccine candidates targeting the Bundibugyo Ebola virus circulating in the Democratic Republic of Congo and Uganda. This is the first major push to create approved vaccines specifically for this virus strain.

The news comes with another encouraging update. Health authorities recently revised their numbers downward, confirming 344 cases in the DRC with 60 deaths, and 15 cases in Uganda with one death. Earlier estimates had suggested over 1,000 suspected cases in the region.

The current situation highlights a crucial gap in our defenses. We already have two approved Ebola vaccines, Ervebo and Zabdeno/Mvabea, but they only work against the Zaire Ebola virus. Different Ebola strains have different surface proteins, meaning existing vaccines can't protect people from the Bundibugyo virus.

Now three teams are racing to fill that gap. The International AIDS Vaccine Initiative is developing what a World Health Organization expert panel called "the most promising candidate vaccine." This single-dose option has already protected macaque monkeys from the Bundibugyo virus, though human trials are still seven to nine months away.

Moderna, the company behind a leading COVID vaccine, is applying its mRNA technology to target the Bundibugyo virus surface protein. The new funding will support both animal studies and human clinical trials.

The University of Oxford and Serum Institute of India are working on a third candidate using technology similar to the Oxford/AstraZeneca COVID vaccine. This option could reach human trials within just two to three months, making it the fastest track forward.

The Bright Side

The speed of this response shows how much we've learned from recent outbreaks. Scientists are applying proven vaccine technologies from COVID to a new challenge, potentially cutting years off the traditional development timeline.

The $62 million investment signals strong global commitment to protecting vulnerable communities. It covers not just development but also the complex work of running clinical trials in remote areas with limited healthcare infrastructure.

Having three different approaches increases the odds that at least one will succeed. If approved, these vaccines would become essential tools not just for this outbreak but for protecting healthcare workers and communities against future Bundibugyo virus threats.

Until vaccines arrive, basic infection control measures remain the primary defense. But the progress happening right now offers real hope that better protection is coming soon for people facing this dangerous disease.